GnRH agonist therapy in gender-affirming care — pausing endogenous puberty at Tanner Stage II while eligibility, monitoring, and future care decisions proceed
Before a GnRH agonist is ever prescribed, adolescents with gender dysphoria undergo a structured, multidisciplinary evaluation. This process — grounded in the WPATH Standards of Care (SOC8) and Endocrine Society Clinical Practice Guidelines — assesses the persistence, consistency, and intensity of gender dysphoria over time, screens for co-occurring mental health considerations, and confirms that the adolescent has entered physiologic puberty. Because GnRH agonists pause an active pubertal process rather than prevent one that has not begun, documented onset of puberty is a clinical prerequisite, not merely a formality.
Guideline-concordant assessment prior to initiating a GnRH agonist involves several coordinated specialties, each contributing a distinct line of evidence:
Pediatric endocrinology: • Confirms pubertal stage by physical exam (Tanner staging) and laboratory testing (LH, FSH, estradiol or testosterone) • Reviews growth curve, bone age (left-hand X-ray), and general health • Assesses for medical contraindications and explains the mechanism, expected effects, and monitoring plan
Mental health assessment: • Evaluates the developmental history and persistence of gender-related identity and dysphoria • Screens for co-occurring conditions (anxiety, depression, autism spectrum considerations) that warrant their own support, without treating them as automatically disqualifying • Assesses the adolescent's capacity to understand the treatment, its purpose, and its reversible nature
Adolescent medicine / pediatrics: • Provides continuity of general care and coordinates family involvement • Supports informed-assent/consent discussions appropriate to the adolescent's developmental stage
Family involvement: • Caregivers participate in psychoeducation and decision-making discussions • Shared decision-making is emphasized throughout, rather than a single gatekeeping decision point
GnRH agonists work by overriding the pulsatile hypothalamic signal that drives an already-active hypothalamic-pituitary-gonadal (HPG) axis. Before puberty begins, the HPG axis is largely quiescent — there is little ongoing pubertal signal to suppress, and treating a prepubertal child would not accomplish the intended purpose.
Clinical confirmation of pubertal onset before starting therapy includes: • Tanner staging by physical exam: breast budding (thelarche) or testicular volume ≥4 mL, typically Tanner Stage II–III • Laboratory confirmation: pubertal-range LH (and LH response to GnRH stimulation testing when needed), rising estradiol or testosterone • Bone age assessment: helps contextualize growth trajectory and epiphyseal maturation
This sequencing matters conceptually: the intervention is accurately described as pausing a puberty that has already started, not preventing puberty from ever occurring.
Guidelines specifically require confirmed Tanner Stage II or above before GnRH agonist initiation. This is a clinical safeguard: it ensures the intervention is used to pause an active, physician-confirmed pubertal process, consistent with its established mechanism and evidence base from decades of use in central precocious puberty.
Eligibility assessment is not a one-time checkpoint but an ongoing process that continues throughout treatment. At each follow-up visit, the care team revisits:
• Whether the adolescent's gender identity and dysphoria remain consistent over time • Physical and psychological response to suppression • Family functioning and support • Readiness to consider next steps, including continuing blockers, discontinuing, or later evaluation for gender-affirming hormone therapy
This iterative structure reflects the guideline principle that puberty blockade is a reversible, time-buying intervention intended to reduce distress from ongoing endogenous puberty while further evaluation and decision-making continue — not a decision that forecloses future options.
Gender-affirming puberty blockers use the same class of medication — GnRH (gonadotropin-releasing hormone) agonists — long used to treat central precocious puberty in younger children. The pharmacology is identical; only the clinical context differs. Continuous, non-pulsatile occupation of pituitary GnRH receptors paradoxically shuts down the reproductive axis, rather than stimulating it, because the pituitary gonadotrope depends on a pulsatile signal to remain responsive.
Under normal physiology, the hypothalamus secretes GnRH in discrete pulses roughly every 60–120 minutes. This pulsatility is essential: pituitary gonadotrope cells are built to respond to intermittent GnRH receptor occupancy by synthesizing and releasing LH and FSH in corresponding pulses.
When a GnRH agonist is administered continuously (via depot injection or implant), GnRH receptors on gonadotrope cells are occupied constantly rather than intermittently. This continuous occupancy triggers:
• Initial "flare": a transient surge in LH/FSH and sex steroids in the first 1–2 weeks, sometimes causing brief symptom flare (spotting, breast tenderness) before suppression sets in • Receptor downregulation: GnRH receptors are internalized and their numbers on the cell surface fall • Post-receptor desensitization: intracellular signaling pathways become unresponsive to further stimulation • Net effect: LH and FSH secretion falls to prepubertal levels within 2–4 weeks
With LH and FSH suppressed, the gonads receive a greatly reduced gonadotropic signal:
• In testes: reduced LH signal lowers Leydig cell testosterone production toward prepubertal levels • In ovaries: reduced LH/FSH signal lowers ovarian estradiol production and halts the follicular cycling that would otherwise lead to menses
Because pubertal physical changes are driven by circulating sex steroids, suppressing their production halts further progression:
• Breast development (thelarche) does not advance further • Testicular/genital growth does not advance further • Voice deepening and facial/body hair growth (androgen-driven) do not progress • Menses do not begin (or, if already present, typically stop)
Critically, changes that occurred before treatment started are not reversed by this mechanism — the medication pauses further progression rather than undoing prior development.
GnRH agonists were developed and extensively studied for central precocious puberty (CPP) — puberty starting abnormally early in children — decades before their use in gender-affirming care. The pharmacology, dosing principles, and monitoring approach are drawn directly from this established evidence base:
• Same drug formulations (leuprolide acetate depot, histrelin implant) • Same expected suppression targets (prepubertal LH, FSH, and sex steroid levels) • Same general reversibility profile upon discontinuation
The distinction between the two clinical uses is the underlying reason for treatment and the age/context in which puberty is being paused — the mechanism of the medication itself is unchanged.
Because GnRH agonist suppression targets the pituitary-gonadal signal rather than sex steroid receptors directly, its effects are mechanistically predictable and, based on decades of use in CPP, reversible upon stopping the medication — a central rationale for its use as a "pause" rather than a permanent intervention.
Once initiated, GnRH agonist therapy follows a structured monitoring protocol: regular dosing to maintain suppression, periodic clinical and laboratory checks to confirm the axis remains suppressed, and interval bone density scanning to track a known, monitored effect of the suppressed-sex-steroid state on the developing skeleton.
Two GnRH agonist formulations are most commonly used:
Depot leuprolide acetate: • Intramuscular injection administered every 1, 3, or occasionally 4 months depending on formulation and dose • Dose titrated to achieve and maintain suppression, confirmed by follow-up labs • Requires ongoing clinic visits for repeat injections
Histrelin acetate subdermal implant: • Small rod-shaped implant placed under the skin of the upper arm under local anesthesia • Provides continuous release of medication for approximately 12 months before requiring replacement • Avoids repeated injections between replacement visits
Choice between formulations is individualized based on patient/family preference, needle tolerance, insurance coverage, and clinic capability for implant placement and removal.
Monitoring during treatment combines clinical and laboratory assessment:
Clinical exam: • Tanner staging at follow-up visits to confirm no further pubertal progression • Growth velocity tracking (height, weight) — pubertal growth spurt should slow toward the suppressed baseline • Review of any breakthrough pubertal symptoms (e.g., menses, further breast/genital development), which may indicate inadequate suppression
Laboratory testing: • LH and FSH: should fall to prepubertal range • Estradiol (natal female patients) or testosterone (natal male patients): should fall to prepubertal range • GnRH stimulation testing is sometimes used in ambiguous cases to directly confirm pituitary desensitization
If suppression is inadequate, dose or interval is adjusted, or formulation is switched.
Sex steroids play an important role in pubertal bone mineral accrual — the period of puberty is normally when a large fraction of peak adult bone mass is laid down. Because GnRH agonists suppress sex steroid production, there is a recognized, monitored theoretical concern that bone mineral density (BMD) accrual may slow during treatment.
Standard monitoring includes: • Baseline DXA (dual-energy X-ray absorptiometry) scan before or shortly after starting treatment • Follow-up DXA scans at roughly yearly intervals while on treatment • Bone density expressed as a Z-score (standard deviations from age- and sex-matched peers), which is tracked over time rather than interpreted as a single snapshot • Attention to calcium and vitamin D intake and weight-bearing activity during treatment
This surveillance is a routine, expected part of the protocol — not a sign that a problem has necessarily occurred — and directly informs discussions about treatment duration and the transition to the next stage of care.
Bone density Z-scores are monitored, not merely measured once, because the clinically relevant question is the trend over the treatment course and its recovery afterward — not an isolated value at any single time point.
A defining clinical feature of GnRH agonist therapy is its reversibility: if the medication is discontinued, the HPG axis reactivates and endogenous puberty resumes within months. This reversibility is central to the clinical rationale for using blockers as a way to create time for further assessment and decision-making, and it also frames how bone density changes during treatment are understood and managed.
GnRH agonist effects depend on continuous receptor occupancy. Once dosing stops and drug clears from circulation:
• Pituitary GnRH receptors are no longer continuously occupied • Receptor density and post-receptor signaling gradually normalize over subsequent weeks • Pulsatile GnRH signaling from the hypothalamus resumes driving pulsatile LH/FSH secretion • Gonadal sex steroid production rises back toward the level appropriate for the individual's pubertal stage • Physical pubertal changes (breast/genital development, menses onset, voice change, body hair) resume progressing from where they had paused
The timeline to full resumption varies between individuals but is generally on the order of months, consistent with decades of experience reversing GnRH agonist treatment in central precocious puberty.
Because sex steroids drive pubertal bone mineral accrual, bone density Z-scores can decline modestly relative to age-matched peers during the period of suppression — this is the theoretical concern that motivates yearly DXA monitoring described in the treatment protocol stage.
What is understood about recovery:
• If blockers are discontinued and endogenous puberty resumes, restored sex steroid exposure supports renewed bone mineral accrual, and bone density typically trends back toward baseline trajectory over time • If the pathway instead continues to gender-affirming hormone therapy (estrogen or testosterone), the sex steroid exposure provided by GAHT similarly supports resumed bone mineral accrual • The clinical practice of yearly DXA monitoring exists specifically to track this trajectory in each individual patient, rather than assuming a fixed population-level outcome
This is why the "pause button" framing extends beyond pubertal development itself to encompass bone health: the intervention's effects on the skeleton are also understood as temporary and monitored, tied to the duration of sex-steroid suppression rather than being a fixed, one-way change.
The reversibility of GnRH agonist suppression — both for pubertal development and for its bone density effects — is the pharmacological basis for describing puberty blockers as a "pause," distinguishing them from interventions with effects that do not resolve upon discontinuation.
The reversible nature of GnRH agonist therapy is the pharmacological basis for its use as a time-creating intervention: it allows an adolescent to avoid some of the physical changes of endogenous puberty that may be a significant source of dysphoria, while the multidisciplinary team, patient, and family continue the assessment process described in the eligibility stage — without the treatment itself foreclosing future options, since stopping the medication allows the individual's own endogenous pubertal trajectory to resume.
GnRH agonist therapy is not an endpoint but a decision-supporting bridge. At an appropriate point — determined individually, not by a fixed calendar — the adolescent, family, and multidisciplinary care team revisit the options: continue blockade, discontinue and allow endogenous puberty to resume, or, following continued eligibility assessment, begin gender-affirming hormone therapy (GAHT). Each pathway remains grounded in the same shared decision-making process established at eligibility assessment.
For some adolescents, continuing puberty blockade for a further period is the appropriate next step — for example, if more time is needed for psychosocial assessment, if the adolescent and family are not yet ready to decide on next steps, or if additional time to consider options is clinically indicated. This requires ongoing monitoring exactly as described in the treatment protocol stage: continued dosing, suppression checks, and bone density surveillance, with the same eligibility-review process revisited at subsequent follow-up visits.
Some adolescents and families decide, after further assessment, not to pursue gender-affirming hormone therapy. In this pathway, the GnRH agonist is stopped and endogenous puberty is allowed to resume and proceed, consistent with the reversibility described in the previous stage. Continued follow-up supports the adolescent through this resumed pubertal process.
For adolescents who, after continued multidisciplinary assessment confirms ongoing eligibility criteria, wish to proceed toward physical changes aligned with their affirmed gender, the pathway is to add gender-affirming hormone therapy (estrogen or testosterone) at an appropriate age, generally in mid-to-later adolescence per current guidelines:
• GnRH agonist suppression is typically continued initially alongside GAHT to prevent competing endogenous sex steroid production, then may be tapered • Estrogen or testosterone is introduced gradually, with dose titration and monitoring analogous in spirit to the suppression monitoring already established • This step is reached through the same eligibility-review and shared decision-making process used throughout — it is a continuation of, not a departure from, the multidisciplinary model described at the outset
Across all three pathways, the process retains the same structure introduced at eligibility assessment: the adolescent's evolving voice, family involvement, and the multidisciplinary care team's ongoing clinical judgment together inform each next step. No single stage of this pathway is treated as irreversible or as foreclosing the others prematurely — the guiding clinical principle throughout is that decisions are revisited over time as the adolescent develops and as more information becomes available.
The continued care pathway illustrates why puberty blockade is often described as creating time rather than making a final decision: the same eligibility-assessment and shared decision-making structure introduced in Stage 1 carries through to whichever pathway is ultimately chosen.